HanAll Biopharma Co. Ltd. has signed an exclusive licensing agreement with Turn Biotechnologies Inc., a pre-clinical stage biopharmaceutical company focused on cellular repair through epigenetic reprogramming—expanding their relationship, which began in 2022 when HanAll made an initial investment in Turn Bio.
ROCKVILLE, Md. and SEOUL, South Korea, May 28, 2024 /PRNewswire/ -- HanAll Biopharma Co., Ltd. (KRX: 009420. KS), a global biopharmaceutical company committed to discovering and developing innovative medicines for patients, has signed an exclusive licensing agreement with Turn Biotechnologies, Inc., a pre-clinical stage biopharmaceutical company focused on cellular repair through epigenetic reprogramming.
MOUNTAIN VIEW, Calif., May 1, 2023 /PRNewswire/ -- Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines for untreatable, age-related conditions, shared data demonstrating the significant potential of using epigenetic reprogramming to rejuvenate skin before an international audience of regenerative aesthetics experts.
MOUNTAIN VIEW, Calif., April 4, 2023 /PRNewswire/ -- Turn Biotechnologies, a cell rejuvenation company developing novel mRNA medicines to cure untreatable, age-related conditions, today announced that Anja Krammer, Chief Executive Officer, will present a corporate overview at the Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days on Tuesday, April 4, 2023 at 1 p.m. EST.